Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial ...

WellSky acquired a California company, its 15th acquisition in the global health and community care technology company's history.

WellSky, a leading health and community care technology company, announced today that it has acquired Bonafide, an enterprise ...

OneroRx, a leading regional provider of pharmacy and telepharmacy services, has acquired two EverCare Pharmacy locations in Princeton and Trenton, Mo., effective Nov. 1.

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

DME, a complication of diabetes ... significant strides in its clinical trials and board appointments. The company has initiated the global Phase 3 LUGANO trial for its Duravyu treatment for ...

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

Full topline results are anticipated in early 2025, with ongoing pivotal trials for wet AMD and DME. According to the company, Duravyu 2.7 mg demonstrated an early and sustained anatomical improvement ...